These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24691062)

  • 1. Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.
    Hadji P; Kyvernitakis J; Albert U; Jockwig J; Kostev K
    Int J Clin Pharmacol Ther; 2014 May; 52(5):352-9. PubMed ID: 24691062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis.
    Hadji P; Ziller V; Kyvernitakis J; Schmidt N; Kostev K
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1149-55. PubMed ID: 23552873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
    Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
    Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid treatment at home: safety data from an observational prospective trial.
    Tassinari D; Poggi B; Nicoletti S; Fantini M; Tamburini E; Possenti C; Sartori S
    J Palliat Med; 2007 Apr; 10(2):352-8. PubMed ID: 17472506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 8. Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
    Crawford BS; McNulty RM; Kraut EH; Turowski RC
    Cancer Invest; 2009 Dec; 27(10):984-8. PubMed ID: 19909013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.
    Diel I; Ansorge S; Hohmann D; Giannopoulou C; Niepel D; Intorcia M
    Support Care Cancer; 2020 Nov; 28(11):5223-5233. PubMed ID: 32086567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
    Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
    J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates.
    Heidenreich A; Witjes WP; Bjerklund-Johansen TE; Patel A;
    Urol Int; 2012; 89(1):30-8. PubMed ID: 22699678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of bisphosphonates in cancer treatment.
    Coleman R
    Ann N Y Acad Sci; 2011 Feb; 1218():3-14. PubMed ID: 20946581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
    Barnadas A; Manso L; de la Piedra C; Meseguer C; Crespo C; Gómez P; Calvo L; Martinez P; Ruiz-Borrego M; Perelló A; Antón A; Codes M; Margelí M; Murias A; Salvador J; Seguí MÁ; de Juan A; Gavilá J; Luque M; Pérez D; Zamora P; Arizcuma A; Chacón JI; Heras L; Martin-Fernández M; Mahillo-Fernández I; Tusquets I
    Bone; 2014 Nov; 68():32-40. PubMed ID: 25108081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
    Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
    Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
    Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
    J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
    Marx RE; Sawatari Y; Fortin M; Broumand V
    J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.